Prospects for a MERS-CoV spike vaccine
Y Zhou, S Jiang, L Du - Expert review of vaccines, 2018 - Taylor & Francis
Introduction: Six years have passed since Middle East respiratory syndrome (MERS)
coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012 …
coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012 …
MERS-CoV spike protein: targets for vaccines and therapeutics
The disease outbreak caused by Middle East respiratory syndrome coronavirus (MERS-
CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was …
CoV) is still ongoing in the Middle East. Over 1700 people have been infected since it was …
Current advancements and potential strategies in the development of MERS-CoV vaccines
N Zhang, S Jiang, L Du - Expert review of vaccines, 2014 - Taylor & Francis
Middle East respiratory syndrome (MERS) is a newly emerging infectious disease caused by
a novel coronavirus, MERS-coronavirus (MERS-CoV), a new member in the lineage C of β …
a novel coronavirus, MERS-coronavirus (MERS-CoV), a new member in the lineage C of β …
Receptor-binding domain-based subunit vaccines against MERS-CoV
N Zhang, J Tang, L Lu, S Jiang, L Du - Virus research, 2015 - Elsevier
Abstract Development of effective vaccines, in particular, subunit-based vaccines, against
emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus …
emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus …
Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus
that was first reported in 2012. The MERS-CoV genome encodes four major structural …
that was first reported in 2012. The MERS-CoV genome encodes four major structural …
[HTML][HTML] Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
J Goo, Y Jeong, YS Park, E Yang, DI Jung, S Rho… - Virus research, 2020 - Elsevier
Abstract Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe
pulmonary infection, with∼ 35% mortality. Spike glycoprotein (S) of MERS-CoV is a key …
pulmonary infection, with∼ 35% mortality. Spike glycoprotein (S) of MERS-CoV is a key …
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen
MP Nyon, L Du, CTK Tseng, CA Seid, J Pollet… - Vaccine, 2018 - Elsevier
Middle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 2040
patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen …
patients and caused 712 deaths since its first appearance in 2012, yet neither pathogen …
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
CM Coleman, T Venkataraman, YV Liu, GM Glenn… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) was first
discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths …
discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths …
Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
J Tang, N Zhang, X Tao, G Zhao, Y Guo… - Human vaccines & …, 2015 - Taylor & Francis
Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by
MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a …
MERS coronavirus (MERS-CoV). The continuous increase of MERS cases has posed a …
[HTML][HTML] Advances in mRNA and other vaccines against MERS-CoV
Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic human
coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory …
coronavirus (CoV). Belonging to the same beta-CoV genus as severe acute respiratory …